Cytosorbents (CTSO) Receivables - Other (2017 - 2025)
Cytosorbents (CTSO) has disclosed Receivables - Other for 9 consecutive years, with $6.0 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other rose 23.77% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Sep 2025, up 23.77%, and an annual FY2024 reading of $4.4 million, up 15.1% over the prior year.
- Receivables - Other was $6.0 million for Q3 2025 at Cytosorbents, down from $6.6 million in the prior quarter.
- Across five years, Receivables - Other topped out at $6.6 million in Q2 2025 and bottomed at $2.8 million in Q1 2021.
- Average Receivables - Other over 5 years is $4.4 million, with a median of $4.3 million recorded in 2022.
- Peak annual rise in Receivables - Other hit 62.34% in 2021, while the deepest fall reached 0.13% in 2021.
- Year by year, Receivables - Other stood at $3.0 million in 2021, then increased by 27.39% to $3.8 million in 2022, then increased by 0.62% to $3.8 million in 2023, then grew by 15.1% to $4.4 million in 2024, then skyrocketed by 35.46% to $6.0 million in 2025.
- Business Quant data shows Receivables - Other for CTSO at $6.0 million in Q3 2025, $6.6 million in Q2 2025, and $5.9 million in Q1 2025.